NCT04261036

Brief Summary

This open-label randomized trial aims at assessing the role of Vitamin C pills in the prevention of catheter-associated urinary tract infections in women undergoing elective gynecological surgeries.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2019

Typical duration for early_phase_1

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 20, 2019

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

February 6, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 7, 2020

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2021

Completed
Last Updated

May 30, 2023

Status Verified

May 1, 2023

Enrollment Period

2 years

First QC Date

February 6, 2020

Last Update Submit

May 26, 2023

Conditions

Keywords

Vitamin CCAUTIAscorbic Acid

Outcome Measures

Primary Outcomes (1)

  • Proportion of participants who experienced clinically diagnosed and treated UTI.

    Urinary tract infection is diagnosed by a positive urine culture.

    14 days

Secondary Outcomes (1)

  • Proportion of participants with asymptomatic bacteruria

    14 days

Study Arms (2)

Women on a vitamin C regimen

EXPERIMENTAL

Women who are undergoing elective gynecological surgeries and who are randomized to take 1g of vitamin C for 14 days.

Drug: Ascorbic Acid 1000 mg

Women on a placebo regimen

PLACEBO COMPARATOR

Women who are undergoing elective gynecological surgeries and who are randomized to take placebo for 14 days

Other: Placebo

Interventions

1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.

Women on a vitamin C regimen
PlaceboOTHER

Placebo pills for 14 days post-op after an elective gynecological surgery.

Women on a placebo regimen

Eligibility Criteria

Age18 Years - 90 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Non pregnant women at least 18 years of age visiting the Preadmission unit (PAU) or the OBGYN floor (7N), presenting for elective GYN surgery at the American University of Beirut Medical Center (AUBMC).

You may not qualify if:

  • Any women with the following:
  • Nephrolithiasis
  • Congenital anomaly or neurogenic bladder
  • Allergy to ascorbic acid
  • Who require therapeutic anticoagulant medicine during the 6 weeks after surgery
  • Surgery did involve a fistula repair or a vaginal mesh removal
  • Positive Urinalysis in the PAU
  • Recurrent UTI's
  • Diabetes
  • G6PD
  • Hemochromatosis
  • Renal disorders
  • Patients already taking Vitamin C supplementation will also be excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

American University of Beirut Medical Center

Beirut, Lebanon

Location

Related Publications (7)

  • Foxman B, Cronenwett AE, Spino C, Berger MB, Morgan DM. Cranberry juice capsules and urinary tract infection after surgery: results of a randomized trial. Am J Obstet Gynecol. 2015 Aug;213(2):194.e1-8. doi: 10.1016/j.ajog.2015.04.003. Epub 2015 Apr 13.

    PMID: 25882919BACKGROUND
  • Ochoa-Brust GJ, Fernandez AR, Villanueva-Ruiz GJ, Velasco R, Trujillo-Hernandez B, Vasquez C. Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy. Acta Obstet Gynecol Scand. 2007;86(7):783-7. doi: 10.1080/00016340701273189.

    PMID: 17611821BACKGROUND
  • Carlsson S, Wiklund NP, Engstrand L, Weitzberg E, Lundberg JO. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide. 2001 Dec;5(6):580-6. doi: 10.1006/niox.2001.0371.

    PMID: 11730365BACKGROUND
  • Trautner BW, Darouiche RO. Catheter-associated infections: pathogenesis affects prevention. Arch Intern Med. 2004 Apr 26;164(8):842-50. doi: 10.1001/archinte.164.8.842.

    PMID: 15111369BACKGROUND
  • Barbosa-Cesnik C, Brown MB, Buxton M, Zhang L, DeBusscher J, Foxman B. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clin Infect Dis. 2011 Jan 1;52(1):23-30. doi: 10.1093/cid/ciq073.

    PMID: 21148516BACKGROUND
  • Hickling DR, Nitti VW. Management of recurrent urinary tract infections in healthy adult women. Rev Urol. 2013;15(2):41-8.

    PMID: 24082842BACKGROUND
  • Wald HL, Ma A, Bratzler DW, Kramer AM. Indwelling urinary catheter use in the postoperative period: analysis of the national surgical infection prevention project data. Arch Surg. 2008 Jun;143(6):551-7. doi: 10.1001/archsurg.143.6.551.

    PMID: 18559747BACKGROUND

MeSH Terms

Interventions

Ascorbic Acid

Intervention Hierarchy (Ancestors)

Sugar AcidsAcids, AcyclicCarboxylic AcidsOrganic ChemicalsHydroxy AcidsCarbohydrates
0

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Masking Details
Vitamin C and Placebo pills will be blindly labeled and assorted in opaque containers in the Pharmacy department according to a computer generated list that allocated random assignment of vitamin C or placebo to a 200 positions (serial numbers from 1 to 200). The research assistant in charge of the recuitment will not be aware of the content of each opaque container and would be providing them to patients according to the order in which they are recruited starting with container number 1, then 2 and so on. The primary care provider and the investigators are blinded as well as they are not aware of the assignment of each recruited patient to placebo vs interventional arm. It is only upon completion of data collection that results would be compared with the randomized generated list in order to link the recruited patients and their collected data with their original assignment to placebo vs intervention.
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Clinical Obstetrics and Gynecology

Study Record Dates

First Submitted

February 6, 2020

First Posted

February 7, 2020

Study Start

July 20, 2019

Primary Completion

July 1, 2021

Study Completion

October 1, 2021

Last Updated

May 30, 2023

Record last verified: 2023-05

Data Sharing

IPD Sharing
Will not share

Locations